Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC)

被引：0
|
作者：
Gulley, James L. [1 ]
Arlen, Philip M. [1 ]
Madan, Ravi [1 ]
Lechleider, Robert L. [1 ]
Dahut, William L. [1 ]
Lowy, Israel [2 ]
Schlom, Jeffrey [1 ]
机构：
[1] NCI, Bethesda, MD USA
[2] Medarex, Princeton, NJ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3381S / 3381S
页数：1
相关论文
共 50 条
  • [31] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates
    Coyne, Geraldine O'Sullivan
    Jochems, Caroline
    Heery, Christopher
    Singh, Harpreet
    Surolia, Ira
    Riley, Robin
    Madan, Ravi
    Dahut, William
    Steinberg, Seth
    Gulley, James
    Schlom, Jeffrey
    CANCER RESEARCH, 2014, 74 (19)
  • [32] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Jochems, Caroline
    Tucker, Jo A.
    Tsang, Kwong-Yok
    Madan, Ravi A.
    Dahut, William L.
    Liewehr, David J.
    Steinberg, Seth M.
    Gulley, James L.
    Schlom, Jeffrey
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (04) : 407 - 418
  • [33] Influence of body mass index (BMI) on PSA kinetics in castrate-resistant prostate cancer (CRPC)
    Teo, M.
    Mayer, N. J.
    Khan, N.
    Sweeney, J. P.
    O'Reilly, S.
    Power, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Beer, T. M.
    Slovin, S. F.
    Higano, C. S.
    Tejwani, S.
    Dorff, T. B.
    Stankevich, E.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pili, R.
    Haggman, M.
    Stadler, W. M.
    Gingrich, J. R.
    Assikis, V. J.
    Bjork, A.
    Forsberg, G.
    Carducci, M. A.
    Armstrong, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC).
    Galsky, MD
    Eisenberger, M
    Moore-Cooper, S
    Kelly, WK
    Slovin, S
    Morales, A
    Curley, T
    Delacruz, A
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 404S - 404S
  • [37] Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P. M.
    Mulquin, M.
    Wright, J. J.
    Turkbey, I. B.
    Choyke, P.
    Ahlers, C. M.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] PSA DECREASE IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER TREATED WITH DEGARELIX
    Bonetta, Alberto
    ANTICANCER RESEARCH, 2012, 32 (05) : 1937 - 1938
  • [39] Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)
    McNeel, Douglas G.
    Chen, Yu-Hui
    Gulley, James L.
    Dwyer, Alexander J.
    Madan, Ravi A.
    Carducci, Michael A.
    DiPaola, Robert S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (10) : 2469 - 2474
  • [40] Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA)
    Logothetis, C. J.
    Wen, S.
    Molina, A.
    Chieffo, N.
    Smith, L. A.
    Troncoso, P.
    Efstathiou, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345